{"id":25135,"date":"2022-10-13T13:31:00","date_gmt":"2022-10-13T05:31:00","guid":{"rendered":"https:\/\/flcube.com\/?p=25135"},"modified":"2025-02-03T13:35:41","modified_gmt":"2025-02-03T05:35:41","slug":"jacobio-partners-with-merck-kgaa-for-kras-g12c-inhibitor-clinical-study","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=25135","title":{"rendered":"Jacobio Partners with Merck KGaA for KRAS G12C Inhibitor Clinical Study"},"content":{"rendered":"\n

China-based Jacobio Pharmaceuticals Group Co., Ltd (HKG: 1167<\/a>) has announced a clinical study collaboration partnership with German giant Merck KGaA (ETR: MRK<\/a>). The focus of the study is the combination of Jacobio\u2019s KRAS G12C inhibitor JAB-21822 with Merck\u2019s cetuximab in KRAS G12C mutant colorectal cancer (CRC). This partnership aims to explore the potential synergistic effects of these two therapies in treating advanced colorectal cancer.<\/p>\n\n\n\n

JAB-21822: Innovative KRAS G12C Inhibitor<\/strong>
Developed in-house by Jacobio, JAB-21822 is an innovative small-molecule anti-cancer drug and a potential best-in-class KRAS G12C inhibitor. The molecule is currently undergoing Phase I\/II clinical studies in advanced solid tumors in China, the US, and Europe. These studies include JAB-21822 as a monotherapy in first-line non-small cell lung cancer or in combination with SHP2 inhibitors or cetuximab.<\/p>\n\n\n\n

Cetuximab: EGFR Targeted Monoclonal Antibody<\/strong>
Erbitux (cetuximab), the world\u2019s first epidermal growth factor receptor (EGFR) targeted IgG1 monoclonal antibody (mAb), was originally developed by ImClone (now wholly owned by Eli Lilly) and licensed to Merck for markets outside of the US and Canada in 1998. Cetuximab targets EGFR, inhibits receptor activation and subsequent signal transduction, reduces tumor cells’ invasion of normal tissues, and prevents the spread to new sites. It also inhibits tumor cells’ ability to repair damage caused by chemotherapy and radiotherapy and blocks the formation of new blood vessels in tumors. In vitro studies have shown that cetuximab exhibits antibody-dependent cytotoxicity (ADCC) against EGFR-positive tumor cells. The drug has been approved in over 100 countries\/regions worldwide for the treatment of RAS wild-type metastatic colorectal cancer, locally advanced and recurrent, and\/or metastatic head and neck squamous cell carcinoma (SCCHN).<\/p>\n\n\n\n

Future Outlook<\/strong>
The collaboration between Jacobio and Merck KGaA underscores the potential of combining innovative KRAS G12C inhibitors with established EGFR-targeted therapies. By exploring the combination of JAB-21822 and cetuximab, the partnership aims to enhance treatment options and improve outcomes for patients with KRAS G12C mutant colorectal cancer.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Jacobio Pharmaceuticals Group Co., Ltd (HKG: 1167) has announced a clinical study collaboration partnership…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[16,29,1147,895,154,120],"class_list":["post-25135","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-cancer","tag-combination-therapy","tag-etr-mrk","tag-hkg-1167","tag-jacobio-pharmaceuticals","tag-merck"],"yoast_head":"\nJacobio Partners with Merck KGaA for KRAS G12C Inhibitor Clinical Study - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Jacobio Pharmaceuticals Group Co., Ltd (HKG: 1167) has announced a clinical study collaboration partnership with German giant Merck KGaA (ETR: MRK). The focus of the study is the combination of Jacobio\u2019s KRAS G12C inhibitor JAB-21822 with Merck\u2019s cetuximab in KRAS G12C mutant colorectal cancer (CRC). This partnership aims to explore the potential synergistic effects of these two therapies in treating advanced colorectal cancer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=25135\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jacobio Partners with Merck KGaA for KRAS G12C Inhibitor Clinical Study\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=25135\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-13T05:31:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-03T05:35:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25135#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25135\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Jacobio Partners with Merck KGaA for KRAS G12C Inhibitor Clinical Study\",\"datePublished\":\"2022-10-13T05:31:00+00:00\",\"dateModified\":\"2025-02-03T05:35:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25135\"},\"wordCount\":340,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Combination therapy\",\"ETR: MRK\",\"HKG: 1167\",\"Jacobio Pharmaceuticals\",\"Merck\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=25135#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25135\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=25135\",\"name\":\"Jacobio Partners with Merck KGaA for KRAS G12C Inhibitor Clinical Study - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-10-13T05:31:00+00:00\",\"dateModified\":\"2025-02-03T05:35:41+00:00\",\"description\":\"China-based Jacobio Pharmaceuticals Group Co., Ltd (HKG: 1167) has announced a clinical study collaboration partnership with German giant Merck KGaA (ETR: MRK). The focus of the study is the combination of Jacobio\u2019s KRAS G12C inhibitor JAB-21822 with Merck\u2019s cetuximab in KRAS G12C mutant colorectal cancer (CRC). This partnership aims to explore the potential synergistic effects of these two therapies in treating advanced colorectal cancer.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25135#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=25135\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25135#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jacobio Partners with Merck KGaA for KRAS G12C Inhibitor Clinical Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Jacobio Partners with Merck KGaA for KRAS G12C Inhibitor Clinical Study - Insight, China's Pharmaceutical Industry","description":"China-based Jacobio Pharmaceuticals Group Co., Ltd (HKG: 1167) has announced a clinical study collaboration partnership with German giant Merck KGaA (ETR: MRK). The focus of the study is the combination of Jacobio\u2019s KRAS G12C inhibitor JAB-21822 with Merck\u2019s cetuximab in KRAS G12C mutant colorectal cancer (CRC). This partnership aims to explore the potential synergistic effects of these two therapies in treating advanced colorectal cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=25135","og_locale":"en_US","og_type":"article","og_title":"Jacobio Partners with Merck KGaA for KRAS G12C Inhibitor Clinical Study","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=25135","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-10-13T05:31:00+00:00","article_modified_time":"2025-02-03T05:35:41+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=25135#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=25135"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Jacobio Partners with Merck KGaA for KRAS G12C Inhibitor Clinical Study","datePublished":"2022-10-13T05:31:00+00:00","dateModified":"2025-02-03T05:35:41+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=25135"},"wordCount":340,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Combination therapy","ETR: MRK","HKG: 1167","Jacobio Pharmaceuticals","Merck"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=25135#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=25135","url":"https:\/\/flcube.com\/?p=25135","name":"Jacobio Partners with Merck KGaA for KRAS G12C Inhibitor Clinical Study - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-10-13T05:31:00+00:00","dateModified":"2025-02-03T05:35:41+00:00","description":"China-based Jacobio Pharmaceuticals Group Co., Ltd (HKG: 1167) has announced a clinical study collaboration partnership with German giant Merck KGaA (ETR: MRK). The focus of the study is the combination of Jacobio\u2019s KRAS G12C inhibitor JAB-21822 with Merck\u2019s cetuximab in KRAS G12C mutant colorectal cancer (CRC). This partnership aims to explore the potential synergistic effects of these two therapies in treating advanced colorectal cancer.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=25135#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=25135"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=25135#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Jacobio Partners with Merck KGaA for KRAS G12C Inhibitor Clinical Study"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25135","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=25135"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25135\/revisions"}],"predecessor-version":[{"id":25136,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25135\/revisions\/25136"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=25135"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=25135"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=25135"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}